Interaction between tumor and immune system: The role of tumor cell biology

Experimental Oncology

Volumn 32, Issue 3, 2010, Pages 159-166

  Berezhnaya, N M ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

CD40; E cadherin; Immunosuppression; LAK; Recognition; Resistance; Tumor cell biology

Indexed keywords

CD40 ANTIGEN; TUMOR ANTIGEN; UVOMORULIN;

ANTIGEN RECOGNITION; BREAST CANCER; CYTOTOXICITY; EXPERIMENTAL NEOPLASM; MELANOMA; OVARY CANCER; REGULATORY T LYMPHOCYTE; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TH17 CELL; TUMOR IMMUNOLOGY; UTERINE CERVIX CANCER;

ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 77957748575     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Berezhnaya NM, Chekhun VF. Immunology of malignant growth. Kiev: Naukova Dumka, 2005, 792 p. (In Russian).
2. Tourkova IL, Shurin GV, Ferrone S, et al. Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunol Immunother 2009; 58: 567-74.
3. Li Z, Cui J, Zhang X, et al. Aflatoxin G1 reduces the molecular expression of HLA-I, TAP-1 and LMP-2 of adult esophageal epithelial cells in vitro. Toxicol Lett 2010; 195: 169-73.
4. Carrega P, Pezzino G, Queirolo P, et al. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 2009; 4: e8132.
5. Chan CJ, Andrews DM, McLaughlin NM, et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184: 902-11.
6. Casado JG, Pawelec G, Morgado S, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009; 58: 1517-26.
7. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557-67. (Pubitemid 37040390)
8. Textor S, Dürst M, Jansen L, et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008; 123: 2343-53.
9. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178-86. (Pubitemid 35244469)
10. Madjd Z, Spendlove I, Moss R, et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 2007; 7: 17.
11. Eisele G, Wischhusen J, Mittelbronn M, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006; 129: 2416-25. (Pubitemid 44522126)
12. Waldhauer I, Steinle A. Proteolytic release of soluble UL16- binding protein 2 from tumor cells. Cancer Res 2006; 66: 2520-6.
13. Hamaï A, Meslin F, Benlalam H, et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res 2008; 68: 9854-64.
14. Schröder C, Schumacher U, Müller V, et al. The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer 2010; 46: 1650-60.
15. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639-44.
16. Lee HM, Choi EJ, Kim JH, et al. A membranous form of ICAM-1 on exosomes efficiently blocks leukocyte adhesion to activated endothelial cells. Biochem Biophys Res Commun 2010; 397: 251-6
17. Bereznaya NM, Chekhun VF. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol 2007; 29: 2-12.
18. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
19. Elmetwali T, Young LS, Palmer DH. CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol 2010; 184: 1111-20.
20. Gabrilovich D, Nagara JS. Myeloid-derived suppressor cells as regulators of immune system. Nature 2009; 9: 162-72.
21. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
22. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
23. Jia W, Jackson-Cook C, Graf MR. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma+vaccination model. J Neuroimmunol 2010; 223: 20-30.
24. + CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009; 182: 111-20.
25. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181: 4666-75.
26. Zhang Y, Liu Q, Zhang M, et al. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182: 3801-8.
27. Su X, Ye J, Hsueh EC, et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010; 184: 1630-41.
28. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL- 17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-9.
29. Berezhnaya NM. The role of immune system cells in the microenvironment of the tumor. 1. The cells and cytokines - inflammation of the participants. Oncology 2009; 11: 6-18. (In Russian).
30. Berezhnaya NM. The role of immune system cells in the microenvironment of the tumor. 2. The interaction of cells in immune with other components of the microenvironment. Oncology 2009; 11: 86-94. (In Russian).
31. Fidler IJ, Kim SJ, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007; 101: 927-36.
32. Osinsky S, Vaupel P. Tumor microphysiology. Kiev: Naukova Dumka, 2009, 256 p. (In Russian).
33. Silzle T, Randolph GJ, Kreutz M, et al. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004; 108: 173-80. (Pubitemid 37541767)
34. Balsamo M, Scordamaglia F, Pietra G, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A 2009; 106: 20847-52.
35. Barkan D, El Touny LH, Michalowski AM, et al. Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. Cancer Res 2010; 70: 5706-16.
36. Migneco G, Whitaker-Menezes D, Chiavarina B, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010; 9: 2412-22.
37. Baird L, Terskikh A. The tumor microenvironment. Adv Exp Med Biol 2010; 671: 67-73.
38. Dützmann S, Gessler F, Harter PN, et al. The promigratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas. Cell Adh Migr 2010; 4: PMID 20595809.
39. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12: 351-65.
40. Mantovani A, Romero P, Palucka AK, et al. Tumour immunity: effector response to tumour and role of the micro-environment. Lancet 2008; 371: 771-83.
41. Lin RK, Wu CY, Chang JW, et al. Dysregulation of p53/ Sp1 control leads to DNA ethyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 70: 5807-17.
42. Chekhun VF, Lukyanova NY, Kovalchuk O, et al. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 2007; 6: 1089-98. (Pubitemid 46554580)
43. Pituch-Noworolska A, Zaremba M, Wieczorek A. Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol 2009; 60: 168-73.
44. van de Ven R, Oerlemans R, van der Heijden JW, et al. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 2009; 86: 1075-87.
45. Savas B, Kerr PE, Pross HF. Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma. Cancer Cell Int 2006; 6: 24. (Pubitemid 44896068)
46. Shafer JA, Cruz CR, Leen AM et al. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma 2010; 51: 870-80.
47. Lundqvist A, Su S, Rao S, Childs R. Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells. J Immunol 2010; 184: 1139-42.
48. Berezhnaya NM, Vinnichuk YD, Konovalenko VF, et al. The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study. Exp Oncol 2005; 27: 303-7.
49. Berezhnaya NM, Vinnichuk YD, Belova OB. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomiosarcoma and B16 melanoma resistant to doxorubicin. Exp Oncol 2008; 30: 52-5.
50. Berezhnaya NM, Belova OB, Vinnichuk YD. Expression of E-cadherin by drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action. Exp Oncol 2009; 31: 242-5.
51. Berezhnaya NM, Kirnasovskaya EA, Vinnichuk YD, et al. Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol 2008; 30: 295-9.